Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Drug Manufacturers - Specialty & Generic

Healthcare
$25.93 -0.71%

-$0.24 today

Market cap
$805.79M
Beta
0.75
P/E (TTM)
14.3
EPS (TTM)
$2.34
52W Low $29.19High $50.79

Volume 0.49M

Average 0.50M

COLL Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Collegium Pharmaceutical, Inc.NASDAQ: COLL

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables broadly unchanged from a year ago

Net receivables stood at $228.76M at the end of Q1 FY2026, up 0.0% from a year earlier and up 8.2% from the prior quarter. Over 3 fiscal years it compounded at +4.9% a year.

Context

  • Net receivables amounted to 13.8% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +0.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$228.76M+8.2% QoQ
Last fiscal yearDec 2025
$211.33M-7.5% YoY
Year agoMar 2025
$228.71M+0.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.0%——
1 year-7.5%——
3-year CAGR+4.9%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
211.33M USD
Year-over-year change
-7.5%
4-year CAGR
+18.9%

Net Receivables vs competitors

How COLL compares with its peers on the latest reported figures

  • COLL's Mar 2026 net receivables of $228.76M is the highest of the 3 companies compared; the peer median is $77.74M.
  • Its year-over-year change of +0.0% is the lowest of 3, against a peer median of +100.5%.
  • Net receivables amounts to 13.8% of total assets for COLL, versus a peer median of 10.3%.
COLL Competitors Peer median
Net Receivables for COLL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
COLLCollegium Pharmaceutical, Inc.Mar 2026$228.76M +0.0%+4.9%13.8%
PCRXPacira BioSciences, Inc.Mar 2026$125.64M +19.9%+8.0%10.4%
SCLXScilex Holding CompanyMar 2026$29.85M +181.1%-10.5%10.2%
LTGOLatigo Biotherapeutics Inc.—— ———
Peer median (excluding COLL) $77.74M+100.5%-1.2%10.3%

Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents186.43M173.69M238.95M70.57M251.1M
Short-term Investments0071.6M92.2M155.43M
Net Receivables105.84M183.12M179.53M228.54M211.33M
Inventory17.39M46.5M32.33M35.56M40.91M
Other Current Assets27K57K93K27.74M3.24M
Total Current Assets315.54M419.99M537.6M482.26M691.41M
Property, Plant & Equipment (Net)27.14M26.38M22.01M20.15M16.2M
Goodwill0133.7M133.86M162.33M145.93M
Intangible Assets268.72M567.47M421.71M891.4M669.51M
Long-term Investments2.55M0001.06M
Tax Assets78.04M23.95M26.26M98.03M112.54M
Other Non-current Assets87K2.65M1.87M9.42M20.19M
Total Non-current Assets376.53M754.14M605.71M1.18B965.42M
Total Assets692.08M1.17B1.14B1.66B1.66B
Account Payables4.19M3.49M8.69M3.93M10.66M
Short-term Debt48.35M162.5M183.33M64.58M30.41M
Tax Payables3.19M4.35M7.15M15.19M0
Deferred Revenue00988K0667K
Other Current Liabilities851K1.51M253.91M7.61M378.73M
Total Current Liabilities279.57M433.73M457.92M509.51M440.03M
Long-term Debt201.63M538.45M483.84M787.91M906.02M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00010M9.11M
Other Non-current Liabilities000121.8M(4.13M)
Total Non-current Liabilities209.58M545.56M489.96M925.24M915.13M
Total Liabilities489.15M979.29M947.88M1.43B1.36B
Common Stock36K37K38K40K41K
Retained Earnings(256.34M)(281.34M)(233.19M)(164M)(101.13M)
Accumulated OCI0014K55K319K
Other Stockholders Equity00000
Minority Interest00000
Total Equity202.93M194.84M195.43M228.84M301.68M
Total Debt258.75M709.18M674.28M859.3M940.56M
Net Debt72.32M535.49M435.34M788.73M689.46M

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Intrinsic Alpha fair value

Locked

Current Price

$25.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.